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Article / Clinical Case Report
ABSTRACT
Undifferentiated carcinoma of the pancreas with osteoclast-like giant cells (UC-OGC) is a rare and poorly described 
pancreatic malignancy. It is comprised of mononuclear, pleomorphic, and undifferentiated cells as well as osteoclast-like 
giant cells (OGC’s). It constitutes less than 1% of pancreatic non-endocrine neoplasia and is twice as likely to occur in 
females as in males. Its histopathologic properties remain poorly understood. It is suspected that UC-OGC is of epithelial 
origin that can then transition to mesenchymal elements. As part of this study, we describe a case of a malignant 
pancreatic neoplasm that was discovered in a 69-year old patient as an incidental finding. We also provide an overview 
of previously published data to highlight UC-OGC’s clinical and pathologic features.  
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INTRODUCTION
Pancreatic carcinoma is the second most common 
type of gastrointestinal malignancy after colorectal 
carcinoma.1,2 Undifferentiated carcinoma of the pancreas 
(UCP) and undifferentiated carcinoma of the pancreas with 
osteoclast-like giant cells (UC-OGC) are rare neoplasms 
that make up 2% of pancreatic malignancies.3,4 UCP can 
be further sub classified into sarcomatoid carcinoma and 
carcinosarcoma.5 UCP has a much poorer prognosis than 
typical ductal adenocarcinoma of the pancreas.1,6 Survival in 
some reports has been on average as low as 5 months 
from the time of diagnosis.3,6 Based on histologic features, 
UCP subtypes and UC-OGC have notable overlap, such 
as the presence of heterologous elements including 
osteoid, muscle and cartilage.6 However, the presence 
of OGC’s is a defining characteristic of UC-OGC in 
the World Health Organization (WHO) classification 
of pancreatic malignancies.7 This entity makes up less 
than 1% of pancreatic malignancies and has a distinct 
histopathological and clinical profile.1,8 We describe a case 
of UC-OGC with sarcomatoid features and abundant 
osteoid production in a previously asymptomatic patient.
CASE REPORT
A 69-year old male with a past medical history 
of chronic hypercholesterolemia, hypertension and 
morbid obesity and remote history of alcohol and 
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tobacco use was incidentally discovered to have 
a 2.5 cm partially calcified, cystic mass within the 
body of the pancreas. The mass was discovered 
as an incidental finding on CT angiogram of the 
abdomen (Figures 1A and 1B) during the evaluation 
for an abdominal aortic aneurysm. Follow-up 
esophagogastroduodenoscopy/endoscopic-ultrasound 
highlighted a 2.7 × 2.6 cm hypoechoic, heterogeneous, 
partially calcified lesion abutting the splenic vein 
(Figure 1).
EUS aspiration revealed a high grade malignant 
neoplasm of uncertain origin. The patient was not 
jaundiced and his total and direct bilirubin, lipase, 
amylase and CA19-9 were within normal limits. He denied 
Figure 1. Abdominal Computed Tomography with intravenous and oral contrast: Sagittal (A) and Coronal (B) views 
demonstrating a well-circumscribed heterogeneous mass within the body of the pancreas (arrowheads), apparently 
without vascular invasion.
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having nausea, vomiting, diarrhea, constipation, 
abdominal pain, appetite changes or bloating. 
The patient subsequently underwent endovascular 
repair of his abdominal aortic aneurysm and his 
recovery remained unremarkable for any gastrointestinal 
symptoms. Six weeks later the patient underwent a 
fine needle aspiration (FNA) of the pancreatic mass 
which demonstrated numerous malignant cells with 
enlarged hyperchromatic nuclei with prominent nucleoli, 
as well as many multinucleated cells. Four weeks 
later the patient underwent an elective exploratory 
laparotomy that consisted of a subtotal pancreatectomy, 
splenectomy and omentectomy. The pancreatic mass 
was found to have dense adhesions around the celiac 
trunk and splenic vessels which necessitated resection of 
the spleen and a portion of the inferior mesenteric vein. 
The lesion was a 3.5 × 2.5 cm firm, brown to yellow, 
well-circumscribed, heterogeneous nodule with focal 
areas of hemorrhage. There was no evidence of tumor 
extending beyond the pancreas.
On microscopic examination, the tumor was 
predominated by pleomorphic, spindle cells associated 
with hemorrhage and abundant hemosiderin pigment 
(Figures 2A and 2B). The spindle cell sarcomatous 
component was diffusely immunoreactive with 
vimentin (Figure 2C). Notably, the tumor contained 
Figure 2. Photomicrography of the pancreatic mass showing in A – Pleomorphic giant cells and malignant spindle 
cells (H&E, 200X); B – hemosiderin and red blood cells (H&E, 200X); C – staining positive for vimentin (200X); and 
D – Ductal carcinoma component (H&E, 200X)
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several well-formed ductal structures (Figure 2D). 
With immunohistochemical staining the glandular 
structures were reactive with CK AE1/AE3 and CK Cam5.2 
(Figures 3A and 3B). Osteoclast-like giant cells were 
present individually and in clusters (Figure 3C), staining 
positive for CD68 (Figure 3D), and were admixed within 
a background of numerous foamy histiocytes (Figure 4A). 
Areas of irregular calcification as well as malignant 
osteoid were evident within the tumor (Figure 4B). 
The foamy macrophages throughout the tumor as well 
as the osteoclast-like giant cells were immunoreactive 
with CD68 and CD31. The malignant spindle cells were 
positive for CD34, while CD31 highlighted adjacent 
foamy macrophages and giant cells (Figures 4C and 4D). 
Several large vacuolated malignant cells were admixed 
with the numerous foamy macrophages that resembled 
lipoblasts. This morphology and immunohistochemistry 
staining pattern was consistent with undifferentiated 
carcinoma of the pancreas with osteoclast-like giant 
cells. No premalignant lesions, including pancreatic 
intraepithelial neoplasia, intraductal papillary mucinous 
neoplasms and mucinous cystic neoplasm were identified.
Microscopically, the tumor did not involve the 
major vessels, including the inferior mesenteric 
vein, celiac trunk or the splenic vessels. These areas, 
however, were surrounded by dense fibrosis.
Figure 3. Photomicrography of the pancreatic mass showing in A – Ductal carcinoma component staining 
positive for CK AE1/AE3 (400X); and Cam 5.2 in B (200X); C – Osteoclast-like giant cells (400X) staining positive 
for CD68 in D (400X).
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DISCUSSION
Tumors with osteoclast-like giant cells have been 
documented within a variety of organs including 
the kidney, breast, thyroid gland, heart, parotid and 
skin.1,7-10 Within the pancreas, they are typically large, 
usually greater than 3.5 cm.3,7,9-12 The mean tumor size 
in reported cases was 5-8 cm.6,7,9-12 The tumor is usually 
a heterogeneous mass that can cause compression of 
adjacent normal structures, or constitutional symptoms 
such as fatigue and weight loss.3,7,9-12 Two-thirds of 
cases in the literature reported abdominal or back 
pain, one-third presented with painless jaundice.6,7,9-12 
One third also reported nausea.6,7,9-12 Weight loss and 
anorexia were also reported in half of the cases.6,7,9-12 
Figure 4. Photomicrography of the pancreatic mass showing in A – Foamy histiocytes (H&E, 100X) and osteoid with 
partial calcification in B (H&E, 100X); C –Tumor staining positive for CD31 (200X) and CD 34 diffusely in D (200X).
CA19-9 was elevated in two-thirds of cases described 
by Muraki et al.6 Our patient was asymptomatic and the 
tumor was discovered incidentally during evaluation 
of an abdominal aortic aneurysm.
UC-OGC is more likely to occur within the body and 
tail of the pancreas, account for about 70% of reported 
cases.6,7,9-12 The majority of cases are diagnosed in the 
sixth to seventh decade of life, when the tumor is in 
late progression. This is mostly due to its asymptomatic 
profile in its early stages.6,7
Radiographically, unlike typical adenocarcinoma 
of the pancreas which is uniformly hypoechoic, 
UC-OGC commonly appears as a heterogeneous 
mass with distinct hyper- and hypoechoic regions.4,7,12 
Pancreatic FNA or biopsy is usually performed in 
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cases of pancreatic malignancies. In Muraki et al’s6 
study, 90% of the cases that underwent preoperative 
biopsy demonstrated malignancy, with a quarter 
having the diagnosis of OGC. Preoperative biopsy 
showed the OGC component was identified in a third 
of cases by Muraki et al.6 Our case demonstrated a 
diagnosis of malignant neoplasm on FNA.
There is much debate in the literature as to the 
origin of the tumor, with many authors favoring 
mesenchymal origin, and others favoring epithelial 
origin.4,6,9-12 Consensus appears to be leaning toward 
an epithelial origin with some authors purporting 
that components of vimentin-positive carcinoma are 
mesenchymal transition from ductal cells.3,6 In reported 
cases, cytokeratin-positive ductal structures have been 
reported to comprise < 5% to 80% of the tumor.6 Our 
case was characterized by rare ductal structures and 
focal immunoreactivity with CK AE1/AE3 and Cam 
5.2 (Figures 2B and 2C), and an atypical mesenchymal 
component with immunoreactivity with vimentin 
(Figure 3B). In a study by Luchini et al.,13 it was 
purported that UC-OGC’s are variants of pancreatic 
ductal carcinoma (PDC) due to the presence of shared 
mutations in KRAS and other critical tumor suppressor 
genes commonly associated with PDC (TP53, CDKN2A 
and SMAD4).
OGCs in UC-OGC consist of benign giant 
cells within a background of infiltrating anaplastic 
mononuclear malignant cells.1,3 They are commonly 
considered to be of benign histiocytic origin, which 
is supported in our case by a lack of atypia, and 
immunoreactivity with CD68. It is hypothesized that 
OGC recruitment is a result of chemotactic factors 
produced by neoplastic cells.7 The presence of large 
sheets of foamy histiocytes within the tumor supports 
the concept of a histiocytic chemotactic factor.7 
Within the OGCs are phagocytized neoplastic cell 
remnants.7 OGCs themselves may be few or may 
comprise the bulk of the tumor, occurring in sheets 
or cell clusters.6 OGCs are typically found in nodules 
associated with areas of hemorrhage. They can fill 
and replace ducts within the pancreas.6 The OGC 
component can comprise the majority of the tumor and 
even resemble an osteoclastoma pattern with minimal 
amounts of the malignant components.6 With a greater 
osteoclast component, a more protracted clinical 
course is expected.6 One third of cases reported in the 
study by Muraki et al.6 had presence of metaplastic, 
mature bone tissue. Many of the cases in the study 
showed associated pancreatitis. OGC and pancreatic 
intraepithelial lesions were observed in 47% of the 
UC-OGC cases.6
UC-OGC usually demonstrates lymph-vascular 
and perineural invasion. In a study by Muraki et al.,6 
lymph-vascular invasion was present in 63% of 
the time in UC-OGC cases. Perineural invasion was 
present in 32% of cases as compared to 86% in 
PDCs (p < 0.0001).6 Our case showed no evidence of 
lymph-vascular or perineural invasion. Muraki et al.6 
found that lymph node metastasis in UC-OGC was less 
as compared to PDC. It was present in 23% of cases 
of UC-OGC and 64% in PDC (p < 0.0001).6 Our case, 
however, showed no regional lymph node metastasis.
UC-OGCs behave differently to other tumors of 
the pancreas. They appear to occur close to a decade 
earlier than PDCs with a mean age of 58 at diagnosis 
compared to 65 years in PDC.6 Although UCP has 
a very poor prognosis with average survival less 
than 1 year, compared to PDC,6 UC-OGC has a 
more favorable prognosis with a 5-year survival rate 
of 59.1% compared to 15.6% for PDC.3,6 Median 
survival in Muraki et al.6 study was 7.7 years compared 
to 1.6 years in patients with PDCs (p<0.0009). In our 
case, the patient has remained clinically free of tumor 
thirteen months post resection. UC-OGC has a 
propensity to invade adjacent structures, although, 
complete resection of the tumor can prove curative 
when the tumor is limited to the pancreas.3,6 Further 
research on this rare entity may help establish reliable 
management guidelines.
CONCLUSION
It is important to differentiate UC-OGC from 
other pancreatic malignancies due to the relative 
improvement in prognosis. Due to its rarity, therapeutic 
guidelines are limited. Further studies may help 
establish treatment modalities and possible molecular 
biomarkers.
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